Nab-paclitaxel plus bevacizumab for patients with previously treated, metastatic extrapulmonary neuroendocrine carcinomas (EP-NECs): A multicentre, open-label, phase II trial

#4420

Introduction: No standard therapies beyond first line are established for advanced EP-NECs. Paclitaxel is also active in NECs however there is no data on the role of nab-paclitaxel.

Aim(s): We conducted a multicentre, open-label, phase II trial to evaluate the efficacy and safety of nab-paclitaxel(nab-PTX) plus bevacizumab(bev) in this setting.

Materials and methods: We included patients (≥18 years) with advanced or metastatic EP-NEC, documented progressive disease after previous therapies. Patients were assigned to receive 150mg/m2 nab-PTX plus 5mg/kg Bev, intravenously, every 2 weeks until disease progression or unacceptable toxicity. The primary end point was OS. Secondary end points included ORR, PFS, DOR, and safety. The study is now complete and is registered with ClinicalTrials.gov, NCT04705519.

Conference:

Presenting Author: Zhang P

Authors: Zhang P, Li S, Li J, Shen L, Lu M,

Keywords: extrapulmonary neuroendocrine carcinoma, nab-paclitaxel, bevacizumab,